TaiGen BioTechnology Nemonoxacin

2022: Entering the Russian market

On October 12, 2022, the R-Pharm Group announced the completion of the registration of the drug non-monoxacin, which is intended for the treatment of community-acquired pneumonia.

Non-monoxacin is an antibiotic - non-fluorinated quinolone. According to the results of clinical trials conducted in China, the drug has demonstrated an effective effect on drug-resistant strains of bacteria (MRSA), including methicillin-resistant staphylococcus aureus, quinolone-resistant staphylococcus aureus and quinolone-resistant pneumococcus.

Registration of non-monoxacin was the result of a large joint project between R-Pharm and TaiGen developer BioTechnology, launched in 2014. Within the framework of the project, an additional multicenter, randomized phase III clinical trial was organized on the territory of the Russian Federation with the participation of 342 people and 26 centers, the results of which formed the basis of the registration dossier of the drug.

Registration of non-monoxacin is an example of a project with a complex implementation scheme. The launch of the drug on the Russian market will make a great contribution to the fight against antibiotic-resistant strains of life-threatening bacteria in our country, "said Vasily Ignatiev, General Director of R-Pharm.

Antibiotic resistance is a "silent pandemic" that can prove itself especially sharply after 2050. And we are glad that R-Pharm will provide patients in Russia with the drug nemonoxacin, which will save tens of thousands of lives annually, "said Kuo-Lung Huang, Chairman of the Board of Directors of TaiGen.